Xinhua Pharma Obtains Three Drug Certificates from Chinese Regulator

MT Newswires Live
09/18

Shandong Xinhua Pharmaceutical (SHE:000756, HKG:0719) and a unit recently obtained drug registration certificates for three drugs from China's National Medical Products Administration.

The company got a certificate for Levocarnitine Oral Solution, used for the treatment of primary systemic carnitine deficiency.

Its Magnesium Sulfate, Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution, which is used for bowel cleaning in adults before any operation requiring intestinal cleansing, also got a registration certificate.

Unit Shandong Zibo Xincat Pharmaceutical got the third certificate for its Donepezil Hydrochloride Orally Disintegrating Tablets for the treatment of mild, moderate or severe symptoms of Alzheimer's disease.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10